Merck + Co., Inc.

Ashley J Yates

David B Karpf

Anastasia G Daifotis

Arthur C Santora, Ii

Deborah Ruth Shapiro

William J Polvino

Desmond E Thompson

Disclosed is a therapy for treating and for preventing periprosthetic bone loss by the administration of a bisphosphonate bone resorption inhibitor, e.g., alendronate, in patients who have an orthopedic implant device.

Alendronate therapy to prevent loosening of, or pain associated with,

Prevention of tooth loss by the administration of alendronate or its

Alendronate, a bisphosphonate, when administered daily over a substantial period of time, can reduce the rate of non-vertebral fractures, in post-menopausal women.

Method of lessening the risk of non-vertebral bone fractures

Bisphosphonate, particularly alendronate, can prevent or treat bone loss associated with immunosuppressive therapy, whether or not the immunosuppressive therapy is associated with an organ transplant.

Bisphosphonates prevent bone loss associated with immunosuppressive

Growing community of inventors

Westfield, NJ, United States of America

Ashley J Yates